



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL**

Applicant : Stegmann, et al.  
App. No : 10/649,480  
Filed : August 27, 2003  
For : METHOD OF PRODUCING  
BIOLOGICALLY ACTIVE HUMAN  
ACIDIC FIBROBLAST GROWTH  
FACTOR AND ITS USE IN  
PROMOTING ANGIOGENESIS  
Examiner : Li, Bao Q.  
Art Unit : 1648

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 13, 2005

(Date)

Che S. Chereskin  
Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Response to Restriction Requirement and Preliminary Amendment in 7 pages.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Che S. Chereskin  
Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stegmann, et al.  
Appl. No. : 10/649,480  
Filed : August 27, 2003  
For : METHOD OF PRODUCING  
BIOLOGICALLY ACTIVE  
HUMAN ACIDIC FIBROBLAST  
GROWTH FACTOR AND ITS  
USE IN PROMOTING  
ANGIOGENESIS  
Examiner : Li, Bao Q  
Group Art Unit : 1648

## RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This paper is responsive to the Restriction / Election of Species Requirement from the Examiner mailed March 23, 2005. It is respectfully requested that the attached preliminary amendment be entered prior to an examination of the claims on the merits.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 7 of this paper.